Long-term sustained release of ganciclovir from biodegradable scleral implant for the treatment of cytomegalovirus retinitis

Journal of Controlled Release

Volumn 68, Issue 2, 2000, Pages 263-271

  Kunou, Noriyuki ^a   Ogura, Yuichiro ^a   Yasukawa, Tsutomu ^b   Kimura, Hideya ^b   Miyamoto, Hideki ^b   Honda, Yoshihito ^b   Ikada, Yoshito ^c  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Biodegradable scleral implant; Cytomegalovirus Retinitis; Ganciclovir; Intraocular drug delivery; Poly (D,L lactide)

Indexed keywords

GANCICLOVIR; POLYLACTIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIODEGRADABLE IMPLANT; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG RELEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; RABBIT; RETINITIS; SCLEROTOMY; SUSTAINED RELEASE FORMULATION; VITREOUS BODY;

ANIMALS; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS RETINITIS; DELAYED-ACTION PREPARATIONS; DRUG IMPLANTS; GANCICLOVIR; RABBITS; VITREOUS BODY;

EID: 0034632944     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(00)00267-4     Document Type: Article

References (39)

1. Holland G.N., Pepose J.S., Pettit T.H., Gottlieb M.S., Yee R.D., Foos R.Y. Acquired immune deficiency syndrome: Ocular manifestations. Ophthalmology. 90:1983;859-873.
2. Palestine A.G., Rodrigues M.M., Macher A.M., Chan C.C., Lane H.C., Fauci A.S., Masur H., Longo D., Reichert C.M., Steis R., Rook A.H., Nussenblatt R.B. Ophthalmic involvement in acquired immunodeficiency syndrome. Ophthalmology. 91:1984;1092-1099.
3. Hennis H.L., Scott A.A., Apple D.J. Cytomegalovirus retinitis. Surv. Ophthalmol. 34:1984;193-203.
4. Jabs D.A., Enger C., Bartlett J.G. Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch. Ophthalmol. 107:1989;75-80.
5. Gross J.B., Bozzete S.A., Mathews W.C., Spector S.A., Abramson I.S., McCutchan J.A., Mendez T., Munguia D., Freeman W.R. Longitudinal study of cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology. 97:1990;681-686.
6. Jabs D.A. Treatment of cytomegalovirus retinitis-1992 [editorial]. Arch. Ophthalmol. 110:1992;185-187.
7. Baril L., Jouan M., Caumes E. The impact of highly active antiretroviral therapy on the incidence of CMV disease in aids patients (abstract). Program and Abstracts of the 37th Interscience Conference On Antimicrpbial Agents and Chemotherapy. 1997;248 American Society for Microbiology.
8. Macdonald J.M., Torriani F.J., Morse L.S. Lack of reactivation of CMV retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevation in CD4 T cells in response to highly active antiretroviral therapy. J. Infect. Dis. 177:1998;1182-1187.
9. Mitchell S.M., Membrey W.L., Youle M.S., Obi A., Worrell S., Gazzard B.G. Cytomegalovirus retinitis after the initiation of highly active antiretroviral therapy: a 2 year prospective study. Br. J. Ophthalmol. 83:1999;652-655.
10. Holland G.N., Sakamoto M.J., Hardy D., Sidikaro Y., Kreiger A.E., Frenkel L.M. Treatment of cytomegalovirus retinopathy in patients with acquired immunodeficiency syndrome. Use of the experimental drug 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine. Arch. Ophthalmol. 104:1986;1794-1800.
11. Henderly D.E., Freeman W.R., Causey D.M., Rao N.A. Cytomegalovirus retinitis and response to therapy with ganciclovir. Ophthalmology. 94:1987;425-434.
12. Jabs D.A., Newman C., de Bustors S., Polk B.F. Treatment of cytomegalovirus retinitis with ganciclovir. Ophthalmology. 94:1987;824-830.
13. Cantrill W.H., Henry K., Melroe N.H., Knobloch W.H., Ramsey R.C., Balfour H.H. Treatment of cytomegalovirus retinitis with intravitreal ganciclovir: long-term results. Ophthalmology. 96:1986;367-374.
14. Cocherau-Massin I., Lehoang P., Lautier-Frau M., Zazun L., Robinet M. Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology. 98:1991;1348-1355.
15. Smith T.J., Pearson P.A., Blandford D.L., Brown J.D., Goins K.A., Hollines J.L., Schmeisser E.T., Glavinos P., Baldwin L.B., Ashton P. Intravitreal sustained-release ganciclovir. Arch. Ophthalmol. 110:1992;255-258.
16. Martin D.F., Parks D.J., Mellow S.D., Ferris F.L., Walton R.C., Remaley N.A., Chew E.Y., Ashton P., Davis M.D., Nussenblatt R.B. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial. Arch. Ophthalmol. 112:1994;1531-1539.
17. Morley M.G., Duker J.S., Ashton P., Robinson M.R. Replacing ganciclovir implants. Ophthalmology. 102:1995;388-392.
18. Martin D.F., Ferris F.L., Parks D.J., Walton R.C., Mellow S.D., Gibbs D., Remaley N.A., Ashton P., Davis M.D., Chen C.C. Timing, surgical procedure, and complications. Arch. Ophthalmol. 115:1997;1389-1394.
19. Kunou N., Ogura Y., Hashizoe M., Honda Y., Hyon S.H., Ikada Y. Controlled intraocular delivery of ganciclovir with use of biodegradable scleral implant in rabbits. J. Control. Rel. 37:1995;143-150.
20. Hashizoe M., Ogura Y., Takanashi T., Kunou N., Honda Y., Ikada Y. Biodegradable polymeric device for sustained intravitreal release of ganciclovir in rabbits. Curr. Eye Res. 16:1997;633-639.
21. Higuchi T. Rate of release of medicaments from ointments base containing drugs in suspension. J. Pharm. Sci. 50:1961;874-875.
22. Pitt C.G., Gratzl M.M., Kimmel G.L., Surles J., Schindler A. Aliphatic polyesters. II. The degradation of poly(DL-lactide), poly(ε-caprolactone) and their copolymers in vivo. Biomaterials. 2:1981;215-220.
23. Li S.M., Garreau H., Vert M. Structure-property relationships in the case of degradation of massive aliphatic poly (α-hydroxy acids) in aqueous media. Part 1: Poly (DL-lactic acid). J. Mater. Sci. Mater. Med. 1:1990;123-130.
24. Li S.M., Garreau H., Vert M. Structure-property relationships in the case of degradation of massive aliphatic poly (α-hydroxy acids) in aqueous media. Part 2: Degradation of lactide-glycolide copolymers, PLA37.5GA25 and PLA75GA25. J. Mater. Sci. Mater. Med. 1:1990;131-139.
25. Li S.M., Garreau H., Vert M. Structure-property relationships in the case of degradation of massive aliphatic poly (α-hydroxy acids) in aqueous media. Part 3: Influence of the morphology of poly (L-lactic acid). J. Mater. Sci. Mater. Med. 1:1990;198-206.
26. Wada R., Hyon S.-H., Ikada Y. Kinetics of diffusion mediated drug release enhanced by matrix degradation. J. Control. Rel. 37:1995;151-160.
27. Pitt C.G., Jeffcoat A.R., Zweidinger R.A., Schindler A. Sustained drug delivery systems. I. The permeability of poly (ε-caprolactone), poly (DL-lactic acid), and their copolymer. J. Biomed. Mater. Res. 68:1979;497-507.
28. Maulding H.V., Tice T.R., Cowsar R.R., Fong J.W., Pearson J.E., Nazareno J.P. Biodegradable microcapsules: acceleration of polymeric excipient. Hydrolytic rate by incorporation of a basic medicant. J. Control. Rel. 3:1986;103-117.
29. Cha Y., Pitt C.G. The acceleration of biodegradation-controlled drug delivery from polyester microspheres. J. Control. Rel. 8:1989;259-265.
30. Juni K., Ogata J., Matsui N., Kubota M., Nakano M. Control of release rate of bleomycin from polylactic acid microspheres by additives. Chem. Pharm. Bull. 33:1985;1609-1614.
31. Bodmeier R., Oh K.H., Chen H. The effect of addition of low molecular weight poly(DL-lactide) on drug release from biodegradable poly(DL-lactide) drug delivery systems. Int. J. Pharm. 51:1989;1-8.
32. Sah H.K., Toddywala R., Chien Y.W. The influence of biodegradable microcapsule formulations on the controlled release of a protein. J. Control. Rel. 30:1994;201-211.
33. Grandfils C., Flandroy P., Jerome R. Control of the biodegradation rate of poly(DL-lactide) microparticles intended as chemoembolization materials. J. Control. Rel. 38:1996;109-122.
34. Geze A., Venier-Julienne M.C., Saulnier P., Varlet P., Daumas-Duport C., Devauchelle P., Benoit J.P. Modulated release of IdUrd from poly(D,L-lactide-co-glycolide) microspheres by addition of poly(D,L-lactide) oligomers. J. Control. Rel. 58:1999;311-322.
35. Mar E.C., Cheng Y.C., Huang E.S. Effect of 9-(1,3-dihydroxy-2-propoxymethyl) guanine on human cytomegalovirus replication in vitro. Antimicrob. Agents Chemother. 24:1983;518-521.
36. Martin J.C., Dvorak C.A., Smee D.F., Matthews T.R., P Verheyden J. 9-(1,3-dihydroxy-2-propoxymethyl) guanine: a new potent and selective antiherpes agent. J. Med. Chem. 26:1983;759-761.
37. Tocci M.J., Livelli T.J., Perry H.C., Crumpacker C.S., Field A.K. Effects of the nucleoside analog 2′-nor-2′-deoxyguanosine on human cytomegalovirus replication. Antimicrob. Agents Chemother. 25:1984;247-252.
38. Plotkin S.A., Drew W.A., Felsenstein D., Hirsch M.S. Sensitivity of clinical isolates of human CMV to 1,3-dihydroxy-2-propoxylmethylguanine. J. Infect. Dis. 152:1985;832-834.
39. Diaz-Llopis M., Martos M.J., Espana E., Cervera M., Ofelia Vila A., Navea A., Molina F.J., Romero F.J. Liposomally-entrapped ganciclovir for the treatment of cytomegalovirus retinitis in AIDS patients. Doc. Ophthalmol. 82:1992;297-305.